GlassScriptPhysician profile
James Eugene Mcdonald
NPI 1326078965
$6,488.95
in general payments reported to CMS, 2019-2025
35 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $310 · 2021: $888 · 2022: $1,321 · 2023: $1,577 · 2024: $1,311 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,961.17 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,499.17 | 2020-2025 | |
| Lilly USA, LLC | $1,179.16 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $635.24 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $441.02 | 2020-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $402.06 | 2021-2024 | |
| Astellas Pharma US INC | $294.61 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $274.31 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $218.00 | 2022 | |
| Exact Sciences Corporation | $183.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $173.43 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.91 | 2020-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $138.76 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $116.21 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $84.65 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $79.69 | 2025 | Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $71.43 | 2022 | |
| Insulet Corporation | $47.87 | 2024 | Omnipod |
| Daiichi Sankyo INC. | $44.40 | 2022-2024 | Injectafer |
| Viatris Specialty LLC | $44.28 | 2025 | Yupelri |
| Dexcom, INC. | $40.77 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $36.56 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $32.39 | 2021 | |
| Boston Scientific Corporation | $32.27 | 2023 | Watchman Flx |
| Paratek Pharmaceuticals, INC. | $30.92 | 2024-2025 | Nuzyra |
| Allergan, INC. | $28.79 | 2020 | |
| Amarin Pharma, INC. | $28.55 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $26.83 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.02 | 2023 | Dupixent |
| Abbott Laboratories | $18.05 | 2022 | |
| Sanofi Pasteur INC. | $17.28 | 2022 | |
| Lundbeck LLC | $15.81 | 2023 | Vyepti |
| Amgen INC. | $15.72 | 2020 | |
| Novo Nordisk INC | $15.20 | 2025 | |
| Becton, Dickinson and Company | $14.35 | 2022 | |
| Seqirus USA INC | $14.10 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.